Atara: 50% Upside, But Cell Therapy Cash Burn Demands a Hold
By stockpickr AI | March 1, 2026 | 10 min read
Investment Summary
Atara Biotherapeutics offers high-risk, high-reward exposure to the developing allogeneic cell therapy space, trading below book value but facing significant R&D cash burn.
Investment Recommendation
Hold
Fair Value: $1.35
Current Price: $0.90
Upside/Downside: +50.0%
The intrinsic value derived from DCF is highly speculative due to uncertain near-term profitability and reliance on future milestones, warranting a cautious stance aligned with current market pricing.
Key Metrics
- No metrics available